Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246639 | SCV001420011 | pathogenic | Hyperammonemia, type III | 2023-06-02 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 970970). Disruption of this splice site has been observed in individual(s) with N-acetylglutamate synthase deficiency (PMID: 15714518, 27570737). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 4 of the NAGS gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NAGS are known to be pathogenic (PMID: 12594532). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. |
Baylor Genetics | RCV001246639 | SCV004199450 | likely pathogenic | Hyperammonemia, type III | 2023-09-05 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001246639 | SCV002093347 | likely pathogenic | Hyperammonemia, type III | 2020-09-14 | no assertion criteria provided | clinical testing |